Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "Ibrutinib"

PHARMACYCLICS : New IMBRUVICA® ibrutinib Application Accepted...

By a News Reporter-Staff News Editor at Biotech Week -- Pharmacyclics, Inc. (NASDAQ: PCYC) announced the acceptance of a Type II variation application for IMBRUVICA(®) (ibrutinib) by the European Medicines Agency (EMA). This submission, filed by ... 4 Traders, 1 week ago
[x]  

21 images for Ibrutinib

British Journal of Haematology, 8 hours ago
Pharmaceutical Journal, 2 days ago
MDLinx, 2 days ago
MDLinx, 2 days ago
MDLinx, 2 days ago
MDLinx, 2 days ago
MDLinx, 2 days ago
MDLinx, 2 days ago
MDLinx, 2 days ago
MDLinx, 2 days ago

New Follow-Up Data for IMBRUVICA(R) (ibrutinib) Presented at ASH Show Longer Term Efficacy in Patients with Chronic Lymphocytic Leukaemia and Mantle Cell Lymphoma

/PRNewswire/ -- Data confirms consistency of IMBRUVICA as an effective treatment option for patients with these challenging blood cancers Janssen-Cilag International NV (Janssen) is pleased to announce the presentation of new longer term ...
 Individual.com1 week ago New follow-up data for IMBRUVICA® (ibrutinib) presented at ASH show longer term efficacy in patients with chronic lymphocytic Leukaemia and mantle cell lymphoma  European Pharmaceutical Review1 week ago
[x]  

Application Submitted to the EMA to Expand the Therapeutic Indication for IMBRUVICA® (ibrutinib) to Include Treatment of Waldenström's Macroglobulinemia

BEERSE, Belgium , December 1, 2014 /PRNewswire/ -- A rare type of B-cell lymphoma for which there are limited treatment options available in Europe Janssen-Cilag International NV (Janssen) announced today the submission of a Type II variation ...
 Sys-Con Italia2 weeks ago
[x]  

TG Therapeutics, Inc. Release: Data From Phase 2 Clinical Trial Of TG-1101 (Ublituximab) And Ibrutinib Shows Compelling Clinical Activity In Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL)

95% (19/20) Overall Response Rate (ORR) in Patients with High-Risk CLL, the patient population to be studied in recently announced Phase 3 Clinical Trial being conducted under Special Protocol Assessment (SPA) 87% (34/39) ORR per iwCLL criteria ...
 BioSpace1 week ago Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL)  A.M. Best1 week ago TG Therapeutics : Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL)  4 Traders1 week ago TG Therapeutics starts Phase I trial of TGR-1202 and ibrutinib combination in CLL and MCL patients  Pharmaceutical Business Review2 weeks ago
[x]  

The Role of Extra-hepatic Metabolism in the Pharmacokinetics of Targeted Covalent Inhibitors Afatinib, Ibrutinib, and Neratinib

Abstract Despite the fact that much progress has been made recently in the development of targeted covalent inhibitors (TCIs), their pharmacokinetics (PK) have not been well characterized in the light of extra-hepatic ...
 Drug Metabolism And Disposition1 week ago

IMBRUVICA(R) (ibrutinib) in Combination with -2-

Patients who are prescribed IMBRUVICA can receive access support through a variety of programs: -- The YOU&i Start(TM) program enables eligible patients who are experiencing insurance coverage delays to access free product for a limited time. ...
 Scottrade1 week ago

Another Washington "Watchdog" Proves to Be a Paper Tiger

The One Drug That Can Give You a 690% Windfall The Pharmacyclics Inc. (Nasdaq: PCYC ) blood-cancer drug Imbruvica (ibrutinib) is well on its way to becoming the blockbuster we predicted when we first recommended shares of the biotech back in ...
 Money Morning1 week ago
Money Morning

Why Ambarella Stock Will Double - Again

The One Drug That Can Give You a 690% Windfall The Pharmacyclics Inc. (Nasdaq: PCYC ) blood-cancer drug Imbruvica (ibrutinib) is well on its way to becoming the blockbuster we predicted when we first recommended shares of the biotech back in ...
 Money Morning1 week ago Will Google Break Up in 2015?  Money Morning2 weeks ago Alibaba Stock Is a Buy Despite This Unusual Set Up  Money Morning2 weeks ago How IBM Stock Can Stop the Bleeding  Money Morning2 weeks ago
Money Morning

Five Reasons Gold Is Higher After Swiss Vote

The One Drug That Can Give You a 690% Windfall The Pharmacyclics Inc. (Nasdaq: PCYC ) blood-cancer drug Imbruvica (ibrutinib) is well on its way to becoming the blockbuster we predicted when we first recommended shares of the biotech back in ...
 Money Morning2 weeks ago
Money Morning

Why the U.S. Treasury Market Is No Longer Safe

The One Drug That Can Give You a 690% Windfall The Pharmacyclics Inc. (Nasdaq: PCYC ) blood-cancer drug Imbruvica (ibrutinib) is well on its way to becoming the blockbuster we predicted when we first recommended shares of the biotech back in ...
 Money Morning2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less